homepage-top-section

The designation has been provided based on Phase II data from the Sprint trial, which evaluated selumetinib as an oral monotherapy in pediatric patients aged three years or

Boehringer Ingelheim, along with nanoPET Pharma, will use the MacroDel biologics-delivery platform to develop novel therapeutics. nanoPET Pharma is a former shareholder of ICD Therapeutics. nanoPET Pharma managing

Zulresso is claimed to be the first and only medicine secured approval to treat PPD, which is the most common medical complication of childbirth. The medicine is an

The EC has approved Tecentriq in combination with Avastin, paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). Tecentriq, in

The recommended dose of Keytruda for the adjuvant treatment of adult patients with melanoma is 200 mg administered as an intravenous infusion over 30 minutes every three weeks

The US Court of Appeals for the Federal Circuit (CAFC) has rejected Indivior’s motion to stay issuance of the mandate following its ruling vacating the preliminary injunction (PI)

The CHMP’s positive opinion for Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel is for the first-line treatment of metastatic NSCLC in adults. Keytruda is an

The first analysis of the tetravalent immunization against dengue efficacy study (TIDES) trial demonstrated that TAK-003 effectively prevented dengue fever caused by any of the four serotypes of

The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According